Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma

Haematologica

Volumn 93, Issue 12, 2008, Pages 1908-1911

  Moreau, Philippe ^a,f   Coiteux, Valerie ^b   Hulin, Cyrille ^c   Leleu, Xavier ^b   Van De Velde, Helgi ^d   Acharya, Milin ^e   Harousseau, Jean Luc ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^e JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^f HÔTEL DIEU   (France)

Author keywords

Bortezomib; Multiple myeloma; Subcutaneous administration

Indexed keywords

BORTEZOMIB; CYTOCHROME P450; PROTEASOME;

ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ENZYME INHIBITION; HUMAN; INJECTION SITE ERYTHEMA; LEUKOPENIA; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; OSTEOSYNTHESIS; PHASE 1 CLINICAL TRIAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; URINARY EXCRETION;

BORONIC ACIDS; DRUG ADMINISTRATION ROUTES; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; PROSPECTIVE STUDIES; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 57349171505     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.13285     Document Type: Article

References (14)

1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20.
2. Millennium Pharmaceuticals Inc. VELCADE® (bortezomib) for injection. Prescribing information. Cambridge, MA, USA 2007; Issued October 2007, Rev 7.
3. Janssen-Cilag International N.V. VELCADE® (bortezomib). Summary of product characteristics. Beerse, Belgium 2007.
4. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165-72.
5. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
6. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
7. Millennium Pharmaceuticals Inc. Data on file.
8. Johnson & Johnson Pharmaceutical Research & Development L.L.C. Data on file.
9. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24:3113-20.
10. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Proteasome inhibition measurements: clinical application. Clin Chem 2000;46:673-83.
11. Bladé J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-23.
12. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-73.
13. Stewart AK, Sullivan D, Lonial S. Pharmacokinetic (PK) and pharmacodynamics (PD) study of two doses of bortezomib (Btz) in patients with relapsed multiple myeloma (MM). 48th Annual Meeting of the American Society of Hematology. Blood 2006 1081008[abstract].
14. Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110:3557-60.